EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

06.18.18

Orrin Hatch, Sponsored the Most by the Pharmaceutical Industry, Tries to Make Its Patents Immune From Scrutiny (PTAB)

Posted in America, Law, Patents at 4:03 am by Dr. Roy Schestowitz

American (US) pharmaceutical patents on Canadian soil are meanwhile at risk as a result of Trump’s trade war that invites retaliation

Orrin Hatch's funding
Source: OpenSecrets

Summary: Orrin Hatch is the latest example of laws being up for sale, i.e. companies can ‘buy’ politicians to act as their ‘couriers’ and pass laws for them, including laws pertaining to patents

THE SCOTUS issued some important rulings such as Alice and Mayo, which meant that patents granted by the USPTO may, in retrospect, be invalid. The Saint Regis Mohawk Tribe is attempting to shield Allergan from the Patent Trial and Appeal Board (PTAB), the only tribunal that can render Allergan’s patents invalid unless Allergan sues. All sorts of pharmaceutical patents are under a similar threat from PTAB and Mr. Kyle Bass made headlines some years ago when he used PTAB as a ‘weapon’. His ‘threat’ was ending a monopoly.

The subject of immunity from PTAB is now at the Federal Circuit and we need to question the motivation of politicians who take Allergan’s side, even based on their sources of funding alone.

“Watchtroll likes to heckle politicians who receive money from technology firms, but what about pharmaceutical firms?”To be clear, in the area of technology pretty much all the companies — both large and small — support PTAB, except a few like IBM, which nowadays relies on patent shakedowns rather than sales (we have been saying this for years [1, 2, 3, 4, 5]). Watchtroll likes to heckle politicians who receive money from technology firms, but what about pharmaceutical firms? Or law firms (third in Orrin Hatch’s list)? We’ll come to that in a moment. In case it’s not obvious, in the pharmaceutical sector the notion of patent trolls is rare and practically ineffective because the number of producing firms is relatively small. It just doesn’t scale. So PTAB is of virtually no use for large pharmaceutical firms; it mostly puts them under the ‘threat’ from generics (we use scare quotes because this the real threat is a threat to people’s lives due to the price of certain medicine — monopolised medicine).

The USPTO’s SAS decision “isn’t good for the efficiency of the PTAB inter-partes review (IPR),” Florian Müller wrote a short time ago (as noted in yesterday's post of ours), unlike Oil States. Here are some passages:

Samsung challenged multiple claims of two of Huawei’s patents-in-suit. The USPTO decided to institute reexamination with respect to some of them, but it had to issue a supplemental order in the wake of SAS and look–nolens volens–at all challenged claims, though it encouraged Samsung to drop its challenge to the ones with respect to which the USPTO was originally unconvinced.

Huawei had actually focused, for the purposes of infringement litigation, on the claims the USPTO viewed more favorably, but the SAS decision changed everything.

As I wrote in my commentary on SAS, this isn’t good for the efficiency of the PTAB inter-partes review (IPR) process, but the conservative Supreme Court majority was right that the way the law was worded didn’t leave room for any other decision, short of legislating from the bench, which most justices declined to engage in.

There have long been attempts to slow down if not shut down PTAB. These attempts came mostly from pharmaceutical giants and the patent microcosm. Days ago we named involvement by Hatch. This anti-PTAB move is now being covered by Dennis Crouch and Watchtroll, who spent his Sunday badmouthing the cause of generics. To quote Crouch’s take (something we already covered twice in recent days, saying we’d check Hatch’s contributions to know if indeed he’s in the pockets of big pharmaceutical companies):

The basics of the amendment is that the results of an IPR/PRG proceeding cannot serve as its Paragraph IV certification that the patent is invalid. A parallel provision is designed for biologics under the BCPIA.

Suddenly everyone starts talking about this; it’s seen as the latest anti-PTAB angle. See Bryan Helwig’s “Life Sciences Court Report” (published hours ago) and this Twitter exchange involving Senior Lecturer Luke McDonagh (who comments a lot on UPC), patent attorney Alexander Esslinger (Team UPC), and Jonathan Kimmelman (Bioethicist/Meta-scientist). “Canada is discussing to make pharmaceutical patents unenforceable in Canada aiming at US pharmaceutical industry as retaliatory action against Donald Trump‘s tariffs IP [sic] trade war,” Esslinger wrote in relation to this article from CBC (Canada). To quote:

And so Attaran is suggesting that Canada take aim at U.S. drug patents.

The U.S. holds more pharmaceutical patents and other intellectual property licences than any other country. But that strength could become a vulnerability if Canada took action to suspend American patents on Canadian soil. Canadian companies would then be able to produce those drugs.

“You hit us on tariffs, we hit you on patents,” he said.

Hours ago Keith Speights published “Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming” — an article in which he says:

How scary is the impending patent cliff? It’s not as bad as you might think.

The worst brunt won’t be felt until 2023. Total sales at risk due to patent expiration will actually be much lower than in recent years in 2020, 2021, and even 2024.

Also, just because sales are at risk doesn’t mean that those sales will completely be lost. EvaluatePharma projects that roughly $139 billion in sales will be lost between 2018 and 2024 for drugs that go off-patent. That’s a big number, but it’s also much lower than the $250-plus billion in sales that are at risk during the period.

Humira, for example, is still expected to be the world’s No. 1 drug in 2024, with sales of more than $15.2 billion. EvaluatePharma thinks that Revlimid will slip a spot from No. 2 to No. 3, but will still grow robustly and generate revenue of close to $8.2 billion annually seven years from now.

Johnson & Johnson has demonstrated the ability to hold on to most of the revenue for Remicade despite losing patent exclusivity. However, J&J’s tactics have been controversial and spurred Pfizer to sue for alleged violation of antitrust laws.

EvaluatePharma’s report noted that many analysts aren’t too concerned about Novo Nordisk’s patent cliff. The firm stated that sales expectations for Novo’s drugs that have or will lose patent protection continue to remain relatively high, probably because of “the historical sales erosion seen for injected diabetes therapy.”

The bottom line is, the value of many companies associated with medicine depends greatly on patents. We do not generally oppose such patents, but we certainly oppose making such patents immune from PTAB. This effort from Hatch is currently being exploited by the anti-PTAB lobby and Hatch seems to be motivated by bribes rather than concerns for public health. Millions of dollars for Hatch to help guard multi-billion monopolies certainly make “business sense”.

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

What Else is New


  1. Links 18/9/2018: Qt 5.12 Alpha , MAAS 2.5.0 Beta, PostgreSQL CoC

    Links for the day



  2. Today's European Patent Office (EPO) Works for Large, Foreign Pharmaceutical Companies in Pursuit of Patents on Nature, Life, and Essential/Basic Drugs

    The never-ending insanity which is patents on DNA/genome/genetics and all sorts of basic things that are put together like a recipe in a restaurant; patents are no longer covering actual machinery that accomplishes unique tasks in complicated ways, typically assembled from scratch by humans; some supposed 'inventions' are merely born into existence by the natural splitting of organisms or conception (e.g. pregnancy)



  3. The EPO Has Quit Pretending That It Cares About Patent Quality, All It Cares About is Quantity of Lawsuits

    A new interview with Roberta Romano-Götsch, as well as the EPO's promotion of software patents alongside CIPA (Team UPC), is an indication that the EPO has ceased caring about quality and hardly even pretends to care anymore



  4. Qualcomm's Escalating Patent Wars Have Already Caused Massive Buybacks (Loss of Reserves) and Loss of Massive Clients

    Qualcomm's multi-continental patent battles are an effort to 'shock and awe' everyone into its protection racket; but the unintended effect seems to be a move further and further away from 'Qualcomm territories'



  5. Links 17/9/2018: Torvalds Takes a Break, SQLite 3.25.0 Released

    Links for the day



  6. The Patent Trial and Appeal Board (PTAB) Helps Prevent Frivolous Software Patent Lawsuits

    PTAB with its quality-improving inter partes reviews (IPRs) is enraging patent maximalists; but by looking to work around it or weaken it they will simply reduce the confidence associated with US patents



  7. Abstract Patents (Things One Can Do With Pen and Paper, Sometimes an Abacus) Are a Waste of Money as Courts Disregard Them

    A quick roundup of patents and lawsuits at the heart of which there's little or no substance; 35 U.S.C. § 101 renders these moot



  8. “Blockchain” Hype and “FinTech”-Like Buzzwords Usher in Software Patents Everywhere, Even Where Such Patents Are Obviously Bunk

    Not only the U.S. Patent and Trademark Office (USPTO) embraces the "blockchain" hype; business methods and algorithms are being granted patent 'protection' (exclusivity) which would likely be disputed by the courts (if that ever reaches the courts)



  9. Qualcomm's Patent Aggression Threatens Rationality of Patent Scope in Europe and Elsewhere

    Qualcomm's dependence on patent taxes (so-called 'royalties' associated with physical devices which it doesn't even make) highlights the dangers now known; the patent thicket has grown too "thick"



  10. Months After Oil States the Patent Maximalists Are Still Desperate to Crush PTAB in the Courts, Not Just in Congress and the Office

    Patent Trial and Appeal Board (PTAB) inter partes reviews (IPRs) improve patent quality and are therefore a threat to those who profit from spurious feuding and litigation; they try anything they can to turn things around



  11. IAM, Watchtroll and the EPO Still Spread the Mentality of Patent Maximalism

    The misguided idea that the objective (overall) should be to grant as many monopolies as possible (to spur a lot of litigation) isn't being challenged in echo chamber 'events', set up and sponsored by think tanks and pressure groups of the litigation 'industry'



  12. Watchtroll and Other Proponents of Patent Trolls Are Trying to Change the Law Outside the Courts in Order to Bypass Patent Justice

    35 U.S.C. § 101 (Section 101) voids almost every software patent — a reality that even the most zealous patent professionals have come to grips with and their way of tackling this ‘problem’ is legislative, albeit nowhere near successful (so far)



  13. Links 16/9/2018: Windows Plays 'Nice' Again, Elisa Music Player 0.3 Beta and Latte Dock 0.8.1

    Links for the day



  14. Slamming Courts and Judges Won't Help the Patent Maximalists; It Can Only Make Things Worse

    Acorda Therapeutics sees its stock price dropping 25% after finding out that its patent portfolio isn't solid, as affirmed by the Federal Circuitn(CAFC); the only way out of this mess is a pursuit of a vastly improved patent quality, thorough patent examination which then offers legal certainty



  15. Patent Trolls Are Still Active and Microsoft is Closely Connected to Many of Them

    A roundup of patent trolls' actions in the United States; Microsoft is connected to a notably high number of these



  16. Advancements in Automobile Technology Won't be Possible With Patent Maximalism

    Advancements in the development of vehicles are being discouraged by a thicket of patents as dumb (and likely invalid) as claims on algorithms and mere shapes



  17. Battistelli “Has Deeply Hurt the Whole Patent Profession, Examiners as Well as Agents” and Also the Image of France

    A French perspective regarding Battistelli's reign at the EPO, which has not really ended but manifests itself or 'metastasises' through colleagues of Battistelli (whom he chose) and another French President (whom he also chose)



  18. António Campinos Needs to Listen to Doctors Without Borders (MSF) et al to Salvage What's Left of Public Consent for the EPO

    Groups including Doctors Without Borders/Médecins Sans Frontières (MSF) and Médecins du Monde (MdM) have attempted to explain to the EPO, with notoriously French-dominated leadership, that it’s a mistake to work for Gilead at the expense of the public; but António Campinos is just another patent maximalist



  19. The Max Planck Institute's Determination on UPC's (Unitary Patent) Demise is Only “Controversial” in the Eyes of Rabid Members of Team UPC

    Bristows keeps lying like Battistelli; that it calls a new paper "controversial" without providing any evidence of a controversy says a lot about Bristows LLP, both as a firm and the individuals who make up the firm (they would not be honest with their clients, either)



  20. Links 15/9/2018: Wine 3.16, Overwatch's GNU/Linux (Wine) 'Ban', New Fedora 28 Build, and Fedora 29 Beta Delay

    Links for the day



  21. Max Planck Institute Pours More Water on the Dying Unitary Patent (UPC)

    The Max Planck Institute gives another sobering reality check for Team UPC to chew on; there's still no sign of any progress whatsoever for the UPC because even Team UPC appears to have given up and moved on



  22. EPO Seals Many Death Sentences With Acceptance of EP 2604620

    Very disappointing news as EP 2604620 withstands scrutiny, assuring that a lot of poor people will not receive much-needed, life-saving treatments



  23. Links 13/9/2018: Compiz Comeback, 'Life is Strange: Before the Storm'

    Links for the day



  24. Now We Have Patents on Rooms. Yes, Rooms!

    The shallow level of what nowadays constitutes "innovation" and merits getting a patent for a couple of decades



  25. EPO Granted a Controversial European Patent (Under Battistelli) Which May Literally Kill a Lot of People

    The EPO (together with CIPA) keeps promoting software patents; patents that are being granted by the EPO literally put lives at risk and have probably already cost a lot of lives



  26. Links 13/9/2018: Parrot 4.2.2, Sailfish OS Nurmonjoki, Eelo Beta

    Links for the day



  27. Patents on Life at the EPO Are a Symptom of Declining Patent Quality

    When even life and natural phenomena are deemed worthy of a private monopoly it seems clear that the sole goal has become patenting rather than advancement of science and technology; media that's controlled by the patent 'industry', however, fails to acknowledge this and plays along with privateers of nature



  28. Defending the World's Most Notorious Patent Trolls in an Effort to Smear the Patent Trial and Appeal Board (PTAB) is an Utterly Poor Strategy

    The 'case' for patent maximalism is very weak; those who spent years if not decades promoting patent maximalism have resorted to attacks on judges, to defense of trolls like Intellectual Ventures, defense of patent scams, and ridiculous attempts to call victims of patent trolls "trolls"



  29. The Belated Demise of Propaganda Sites of the Litigation 'Industry'

    Sites that promote the interests of Big Litigation (patent trolls, patent law firms etc.) are ebbing away; in the process they still mothball the facts and push propaganda instead



  30. Links 11/9/2018: OpenSSL 1.1.1, Alpine Linux 3.8.1, Copyright Fight in EU

    Links for the day


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts